Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4-dihydropyrimidin-1 (2H)- y!)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t- butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1 (2H)-yl)2-methoxy-styryl- phenyl)methanesulfonamide.
本申请涉及一种用于治疗丙型肝炎(HCV)感染的化合物,其
化学式为I。所述化合物的结构中,尿
嘧啶或胸腺
嘧啶衍
生物通过苯基与融合的2环环系统(R6)或者通过额外的两原子连接物(L)与5-6环单环(R6)相连。该申请还揭示了两种特定化合物的多晶形和伪多晶形:N-(6(3-叔丁基-5-(2>4-二氧化-3,4-二氢
嘧啶-1(2H)-基)2-
甲氧基苯基)
萘-2-基)甲磺酰胺和(E)-N-(4(3-叔丁基-5-(2,4-二氧化-3,4-二氢
嘧啶-1(2H)-基)2-甲氧基-
苯乙烯基苯基)甲磺酰胺。